Lohman Technologies Welcomes Accomplished Healthcare Innovator Dr Nick Turkal to its Board of Directors

Dr. Nick Turkal joins Lohman’s Board of Directors, strengthening leadership in the remote cardiac care solution company.

Lohman Technologies proudly announces the appointment of Dr. Nick Turkal to its esteemed Board of Directors. This strategic addition reinforces Lohman’s commitment to advancing innovation, driving growth, and shaping the future of remote cardiac monitoring solutions.

With an illustrious career spanning 30 years, Dr Nick Turkal brings a wealth of expertise and a proven track record in the healthcare industry. Dr. Turkal’s visionary leadership, combined with a deep understanding of the dynamic healthcare landscape will contribute significantly to Lohman’s ongoing success.

“We are thrilled to welcome Dr. Turkal to our board,” said Jason Dvorak, President of Lohman Technologies. “His extensive experience and on-going passion for improving access for all patients aligns seamlessly with our mission to continuously improve and impact the care continuum through innovative remote cardiac monitoring, collaborative partnerships, and the promotion of health equity. Dr. Turkal will play a pivotal role in guiding our company.”

In addition to serving Lohman Technologies as a Board Member, Dr, Turkal serves as Chief Medical Advisor to Lohman and sits on the Board of the Crisis Prevention Institute (CPI). He is also past Chair of the Wisconsin Hospital Association Board and served on the Boards of Blood Center of Wisconsin, StartUp Health, abouthealth, Premier and the Greater Milwaukee Committee, MMAC, United Way, American Hospital Association Governing Council, numerous academic institutions, including Creighton University, Burrell College of Osteopathic Medicine, and Idaho College of Osteopathic Medicine. Turkal also served as a Board member for Advocate Aurora Health while CEO.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”